Cullinan Management CGEM 深 沪
已收盘 12-19 16:00:00 美东时间
9.68
-0.300
-3.01%
华盛通- 最 高10.14
- 今 开10.13
- 成交量 187.02万股
- 最 低 9.61
- 昨 收 9.98
- 总市值 5.72亿
- 52周最高 13.33
- 市盈率 静 --
- 换手率 3.17%
- 52周最低 5.68
- 委 比 -8.69%
- 总股本 5907.44万
- 历史最高 59.85
- 量 比 1.48
- 振 幅 5.31%
- 历史最低 5.68
- 每 手 1
- 风险率 1.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Cullinan Therapeutics Presents Promising CLN-049 Data
Cullinan Management ( ($CGEM) ) has issued an announcement. On December 8, 2025...
12-08 23:57
Cullinan Therapeutics Reports CLN-049 Monotherapy Efficacy With Multiple Complete Responses And Durable Activity In Heavily Pretreated R/R AML Patients, Achieves 31% CR/CRh At Highest Dose, Demonstrates Favorable Safety Across Doses; Phase 1 Data Presented At ASH 2025
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML31% CR/CRh rate
12-08 23:35
Cullinan Therapeutics Says FDA Granted Fast Track Designation To CLN-049 For Treatment Of Relapsed/Refractory Acute Myeloid Leukemia
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patientsCAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE)
12-01 20:14
美股牛股 | OSCR大涨超22%，白宫计划延长奥巴马医改补贴；加密财库公司BitMine大涨19.6%
OSCR大涨超22%，白宫计划延长奥巴马医改补贴；加密财库公司BitMine大涨19.6%，持有3%的ETH代币供应量>>
11-25 15:10
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Advanced Biomed (NASDAQ:ADVB) stock rose 29.6% to $0.48 during Monday'...
11-25 01:05
Cullinan Management Ends Development of CLN-617
Cullinan Management ( ($CGEM) ) has provided an announcement. On November 18, 2...
11-22 06:03
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Taiho Oncology, Taiho Pharma And Cullinan Therapeutics Initiate Rolling Submission Of NDA To FDA Seeking Accelerated Approval Of Zipalertinib For NSCLC Treatment
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) today announced the companies have initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and
11-20 20:15
